Cabaletta BioCABA +1.32%34 Quick Ratio is 2.95 as of Mar. 2026, which is 81% below its 10-year median of 15.29. GuruFocus rates CABA with a GF Score™ of 34/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, Cabaletta Bio ranks worse than 56.18% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Cabaletta Bio's quick ratio for the quarter that ended in Mar. 2026 was 2.95.
Cabaletta Bio has a quick ratio of 2.95. It generally indicates good short-term financial strength.
The historical rank and industry rank for Cabaletta Bio's Quick Ratio or its related term are showing as below:
CABA'
s Quick Ratio Range Over the Past 10 Years
Min: 2.77 Med: 15.29 Max: 44.66
Current: 2.95
During the past 9 years, Cabaletta Bio's highest Quick Ratio was 44.66. The lowest was 2.77. And the median was 15.29.
CABA's Quick Ratio is ranked worse than 56.18% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs CABA: 2.95
Cabaletta Bio (NAS:CABA) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Cabaletta Bio Quick Ratio Related Terms
Cabaletta Bio Quick Ratio Historical Data
* Premium members only.
The historical data trend for Cabaletta Bio's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Cabaletta Bio's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cabaletta Bio Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cabaletta Bio's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Cabaletta Bio's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Cabaletta Bio's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cabaletta Bio (CABA) has a Quick Ratio of 2.95 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cabaletta Bio and its competitors. This is 81% below median its historical median of 15.29. Over the past decade, Cabaletta Bio's Quick Ratio has ranged from 2.77 to 44.66. According to the industry distribution chart, Cabaletta Bio ranks #796 out of 1417 companies in the Biotechnology industry, placing it in the top 56.2%.
Is Cabaletta Bio's Quick Ratio too high?
Cabaletta Bio's current Quick Ratio of 2.95 is 81% below median its 10-year median of 15.29. Over the past 10 years, this metric has ranged from a low of 2.77 to a high of 44.66. The Biotechnology industry median Quick Ratio is 3.60. Cabaletta Bio's value of 2.95 is 18.1% below this industry median. Based on the distribution chart, Cabaletta Bio ranks #796 out of 1417 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Cabaletta Bio has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Cabaletta Bio's Quick Ratio compare to DNA and CADL?
According to the Biotechnology industry distribution chart, Cabaletta Bio ranks #796 out of 1417 companies for Quick Ratio. This places Cabaletta Bio in the lower half of its industry. The industry median Quick Ratio is 3.60. Cabaletta Bio's value of 2.95 is 18.1% below this benchmark. Historically, Cabaletta Bio's own Quick Ratio has ranged from 2.77 to 44.66 over the past decade. While the company's 10-year median is 15.29 vs. the industry median of 3.60, Cabaletta Bio has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Cabaletta Bio's current Quick Ratio of 2.95 is 18.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Cabaletta Bio and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cabaletta Bio's current Quick Ratio is 2.95, which is 81% below median its own 10-year median of 15.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cabaletta Bio stock overvalued right now?
Cabaletta Bio (CABA) has a current Quick Ratio of 2.95. The current Quick Ratio is 2.95, which is 81% below median its 10-year median of 15.29 and 18.1% below the Biotechnology industry median of 3.60. Cabaletta Bio's overall GF Score™ is 34/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Cabaletta Bio (CABA), the current Quick Ratio is 2.95 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Cabaletta Bio Inc is a late clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for autoimmune diseases. Its proprietary Cabaletta Approach to B cell Ablation (CABA) platform includes the CARTA approach, which uses chimeric antigen receptor T cells to eliminate B cells and potentially reset the immune system. The company develops cellular therapies including CAR T and CAAR T product candidates. Its candidate, rese-cel (resecabtagene autoleucel), a CD19-CAR T cell therapy, is being evaluated in Phase 1/2 trials for autoimmune diseases such as systemic lupus erythematosus, myositis, systemic sclerosis, generalized myasthenia gravis, and pemphigus vulgaris.
34GF Score
Get the complete analysis for CABA
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CABA has been successfully added to your 
